静脉免疫球蛋白G治疗坏死性软组织感染(INSTINCT):一项随机、盲法、安慰剂对照试验
INSTINCT试验将100例坏死性软组织感染患者1:1随机分配至静脉注射免疫球蛋白G(Privigen,25 g,每日一次,ICU入住前3天)或等量0.9%生理盐水安慰剂组。主要终点为随机化后6个月36项短期健康调查(SF-36)的躯体功能综合评分(PCS),死亡患者计最低分0分。纳入意向性治疗分析的87例中,免疫球蛋白G组42例(84%)、安慰剂组45例(90%);两组中位PCS评分分别为36(四分位距0-43)和31(0-47),平均校正差值1(95%置信区间-7至10),p=0.81。结论认为在ICU坏死性软组织感染患者中,辅助静脉免疫球蛋白G对6个月自报躯体功能未见明显效果。
要点
- 在ICU坏死性软组织感染患者中,辅助静脉免疫球蛋白G 25 g每日一次用3天,6个月SF-36躯体功能综合评分与安慰剂无显著差异(平均校正差值1,95%置信区间-7至10,p=0.81)。
- 免疫球蛋白G组6个月中位PCS评分为36(四分位距0-43),安慰剂组为31(0-47),死亡患者均计0分。
- 意向性治疗分析纳入87例(免疫球蛋白G组42例、安慰剂组45例),两组基线特征除随机化前免疫球蛋白G使用(允许1剂)和急性肾损伤发生率外相似。
- 按基线预后因素校正、符合方案集分析、按坏死性软组织感染部位亚组分析及随机化前免疫球蛋白G使用事后校正分析,均支持主要结果。
- 该试验未观察到辅助静脉免疫球蛋白G对坏死性软组织感染ICU患者6个月自报躯体功能的明显效果。
适用人群与场景
- ICU坏死性软组织感染患者,随机化前允许使用1剂免疫球蛋白G。
处置流程与药物剂量
- 免疫球蛋白G组:静脉注射Privigen 25 g,每日一次,ICU入住前3天给药;安慰剂组:等量0.9%生理盐水,同样每日一次用3天。
研究设计与关键结果
- 研究类型:随机、盲法、安慰剂对照试验(INSTINCT),样本量100例,1:1随机分配至静脉免疫球蛋白G组或安慰剂组。
- 主要终点:随机化后6个月SF-36躯体功能综合评分(PCS),死亡患者计最低分0分;纳入意向性治疗分析87例,免疫球蛋白G组42例(84%)、安慰剂组45例(90%)。
- 主要结果:免疫球蛋白G组中位PCS评分36(四分位距0-43),安慰剂组31(0-47),平均校正差值1(95%置信区间-7至10),p=0.81。
- 支持性分析:按基线预后因素校正、符合方案集分析、按坏死性软组织感染部位亚组分析及随机化前免疫球蛋白G使用事后校正分析,结果与主要分析一致。
证据类型、等级与局限
- 证据类型:随机、盲法、安慰剂对照试验(INSTINCT),试验注册号NCT02111161。
- 局限:原文未报告局限性
对床旁实践的改变
- 在ICU坏死性软组织感染患者中,辅助静脉免疫球蛋白G 25 g每日一次用3天未显示对6个月自报躯体功能有明显效果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The aim of the INSTINCT trial was to assess the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo on self-reported physical function in intensive care unit (ICU) patients with necrotising soft tissue infection (NSTI).
METHODS: We randomised 100 patients with NSTI 1:1 to masked infusion of 25 g of IVIG (Privigen, CSL Behring) or an equal volume of 0.9% saline once daily for the first 3 days of ICU admission. The primary outcome was the physical component summary (PCS) score of the 36-item short form health survey (SF-36) 6 months after randomisation; patients who had died were given the lowest possible score (zero).
RESULTS: Of the 100 patients randomised, 87 were included in the intention-to-treat analysis of the PCS score, 42 patients (84%) in the IVIG group and 45 patients (90%) in the placebo group. The two intervention groups had similar baseline characteristics with the exception of IVIG use before randomisation (1 dose was allowed) and rates of acute kidney injury. Median PCS scores were 36 (interquartile range 0-43) in the group assigned to IVIG and 31 (0-47) in the group assigned to placebo (mean adjusted difference 1 (95% confidence interval -7 to 10), p = 0.81). The result was supported by analyses adjusted for baseline prognostics, those in the per protocol populations, in the subgroups (site of NSTI) and those done post hoc adjusted for IVIG use before randomisation.
CONCLUSIONS: In ICU patients with NSTI, we observed no apparent effects of adjuvant IVIG on self-reported physical functioning at 6 months.
TRIAL REGISTRATION: NCT02111161.
参考来源
- Madsen MB, Hjortrup PB, Hansen MB, et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med. 2017. PMID: 28421246. doi:10.1007/s00134-017-4786-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。